Arbutus Biopharma Corp
ABUS- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001447028
No open-market purchases or sales by Arbutus Biopharma Corp insiders were filed in the last 90 days; 176 institutions reported holding it in 13F filings for Q2 2026, worth $674.9M in total; no superinvestor holds it.
Q1 2025 vs. Q4 2024
How the institutions holding Arbutus Biopharma Corp changed between Q4 2024 and Q1 2025.
All holders in Q1 2025All holders in Q4 2024
| Measure | Q4 2024 | Of which not filed for Q1 2025 | Q1 2025 | Change |
|---|---|---|---|---|
| Holders | 154 | 3 | 168 | +17 |
| Shares | 104.1M | 1.02M | 111.8M | +8.72M (+8.5%) |
| Value | $340.3M | $3.32M | $390.1M | +$53.1M (+15.8%) |
3 institutions that held it in Q4 2024 haven't filed for Q1 2025 yet. Not filing isn't selling, so the changes leave them out.
New holders (26)
Institutions that held Arbutus Biopharma Corp at the end of Q1 2025 but not at the end of Q4 2024.
Sold out (9)
Institutions that held Arbutus Biopharma Corp at the end of Q4 2024 and filed for Q1 2025 without it.
| Institution | Shares, Q4 2024 | Value, Q4 2024 |
|---|---|---|
| LMR Partners LLP | 158,249 | $517.5K |
| Ballentine Partners, LLC | 31,121 | $101.8K |
| Centiva Capital, LP | 30,724 | $100.5K |
| Exome Asset Management LLC | 28,300 | $92.5K |
| Virtus ETF Advisers LLC | 19,970 | $65.3K |
| Two Sigma Securities, LLC | 19,475 | $63.7K |
| E Fund Management Co., Ltd. | 10,385 | $34.0K |
| CIBC Private Wealth Group, LLC | 5,450 | $18.3K |
| SRS Capital Advisors, Inc. | 1,206 | $3.94K |
Not filed for Q1 2025 yet (3)
Institutions that held Arbutus Biopharma Corp at the end of Q4 2024 and haven't filed a 13F for Q1 2025. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q4 2024 | Value, Q4 2024 |
|---|---|---|
| Corbin Capital Partners, L.P. | 682,487 | $2.23M |
| Nuveen Asset Management, LLC | 313,307 | $1.02M |
| Kades & Cheifetz LLC | 20,000 | $65.4K |